Switching from a first to a second tumour necrosis factor (TNF) alpha antagonist in patients with juvenile idiopathic arthritis

被引：0
|
作者：
H Schmeling
G Horneff
机构：
[1] Hospital for Sick Children,
[2] Asklepios Klinik,undefined
来源：
Pediatric Rheumatology | / 6卷 / Suppl 1期
关键词：
Public Health; Adverse Event; Arthritis; Tumour Necrosis; Tumour Necrosis Factor;
D O I：
10.1186/1546-0096-6-S1-P41
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] DRUG SURVIVAL OF SECOND BIOLOGIC DMARD THERAPY IN PATIENTS WITH RHEUMATOID ARTHRITIS: COMPARISON OF A SECOND ANTI-TUMOUR NECROSIS FACTOR WITH A SECOND NON-ANTI-TUMOUR NECROSIS FACTOR AFTER DISCONTINUATION OF A FIRST ANTI-TUMOUR NECROSIS FACTOR
    Wilke, Thomas
    Mueller, Sabrina
    Majer, Istvan
    Heisen, Marieke
    Fuchs, Andreas
    Maywald, Ulf
    RHEUMATOLOGY, 2016, 55 : 105 - 105
  • [32] Polymorphisms in Tumour Necrosis Factor Alpha (TNFα) Gene in Patients with Acute Pancreatitis
    Ozhan, Gul
    Yanar, Hakan T.
    Ertekin, Cemalettin
    Alpertunga, Buket
    MEDIATORS OF INFLAMMATION, 2010, 2010
  • [33] Treatment of psoriatic arthritis with etanercept, a tumour necrosis factor antagonist
    Wong, VK
    Lebwohl, MG
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2005, 5 (11) : 1505 - 1513
  • [34] Treatment Effectiveness Following Switching from Initial TNF Inhibitor in Juvenile Idiopathic Arthritis
    Ong, Mei-Sing
    Ringold, Sarah
    Mannion, Melissa
    Natter, Marc
    Kimura, Yukiko
    ARTHRITIS & RHEUMATOLOGY, 2024, 76 : 773 - 775
  • [35] Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor?
    Hjardem, Elisabeth
    Ostergaard, Mikkel
    Podenphant, Jan
    Tarp, Ulrik
    Andersen, Lis Smedegaard
    Bing, Jette
    Peen, Elisabeth
    Lindegaard, Hanne Merete
    Ringsdal, Vibeke Stevenius
    Rodgaard, Anne
    Skot, Jens
    Hansen, Annette
    Mogensen, Hans Henrik
    Unkerskov, Janne
    Hetland, Merete Lund
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (09) : 1184 - 1189
  • [36] Analysis of the levels of tumour necrosis factor (TNF), autoantibodies to TNF, and soluble TNF receptors in patients with rheumatoid arthritis
    Lopatnikova, J. A.
    Golikova, E. A.
    Shkaruba, N. S.
    Sizikov, A. E.
    Sennikov, S. V.
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2013, 42 (06) : 429 - 432
  • [37] Switching between anti-TNFα (tumour necrosis factor-alpha) agents in the treatment of rheumatoid arthritis (RA) -: A DGH experience
    Bawa, S.
    Wong, E.
    Ang, J. E.
    Hall, J.
    Mukhtyar, C.
    Bufton, C.
    McNally, J.
    Edmonds, S.
    Webley, M.
    RHEUMATOLOGY, 2006, 45 : I52 - I52
  • [38] Tumour necrosis factor α G→A-238 and G→A-308 polymorphisms in juvenile idiopathic arthritis
    Ozen, S
    Alikasifoglu, M
    Bakkaloglu, A
    Duzova, A
    Jarosova, K
    Nemcova, D
    Besbas, N
    Vencovsky, J
    Tuncbilek, E
    RHEUMATOLOGY, 2002, 41 (02) : 223 - 227
  • [39] UTILIZATION OF TUMOR NECROSIS FACTOR ALPHA INHIBITORS IN CHILDREN AND YOUNG ADULTS WITH JUVENILE IDIOPATHIC ARTHRITIS
    Lee, W.
    Briars, L. A.
    Lee, T. A.
    Calip, G. S.
    Suda, K. J.
    Schumock, G.
    VALUE IN HEALTH, 2016, 19 (03) : A227 - A227
  • [40] Experiences with tumour necrosis factor-α inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry
    Sevcic, Krisztina
    Orban, Ilonka
    Brodszky, Valentin
    Bazso, Anna
    Balogh, Zsolt
    Poor, Gyula
    Kiss, Emese
    RHEUMATOLOGY, 2011, 50 (07) : 1337 - 1340
12345